Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Merck
Johnson and Johnson
Boehringer Ingelheim
Moodys

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

COMBIGAN Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Combigan patents expire, and when can generic versions of Combigan launch?

Combigan is a drug marketed by Allergan and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in nineteen countries.

The generic ingredient in COMBIGAN is brimonidine tartrate; timolol maleate. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the brimonidine tartrate; timolol maleate profile page.

US ANDA Litigation and Generic Entry Outlook for Combigan

  Start Trial

Combigan was eligible for patent challenges on December 31st, 1968.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 19th, 2022. This may change due to patent challenges or generic licensing.

Annual sales in 2017 were $215mm indicating the motivation for generic entry (peak sales were $398mm in 2016).

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are three tentative approvals for the generic drug (brimonidine tartrate; timolol maleate), which indicates the potential for near-term generic launch.

Drug patent expirations by year for COMBIGAN
Drug Prices for COMBIGAN

See drug prices for COMBIGAN

Drug Sales Revenue Trends for COMBIGAN

See drug sales revenues for COMBIGAN

Generic Entry Opportunity Date for COMBIGAN
Generic Entry Date for COMBIGAN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for COMBIGAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
EMSPhase 3
McMaster UniversityN/A
Carmel Medical CenterPhase 2

See all COMBIGAN clinical trials

Recent Litigation for COMBIGAN

Identify potential future generic entrants

District Court Litigation
Case NameDate
ALLERGAN SALES, LLC v. SANDOZ, INC.2017-10-30
Allergan Sales, LLC v. Sandoz, Inc.2017-01-19
Allergan, Inc. v. Sandoz, Inc.2012-04-13

See all COMBIGAN litigation

PTAB Litigation
PetitionerDate
Ferrum Ferro Capital, LLC2015-03-09

See all COMBIGAN litigation

Synonyms for COMBIGAN
2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (2S)-, mixt. with 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine
952743-07-6
Brimonidine / timolol
Brimonidine mixture with timolol
Brimonidine tartrate / timolol maleate
Brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
Brimonidine tartrate and timolol maleate
Brimonidine Tartrate, Timolol Maleate Drug Combination
SCHEMBL5873369
Paragraph IV (Patent) Challenges for COMBIGAN
Tradename Dosage Ingredient NDA Submissiondate
COMBIGAN SOLUTION/DROPS;OPHTHALMIC brimonidine tartrate; timolol maleate 021398 2008-11-21

US Patents and Regulatory Information for COMBIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398-001 Oct 30, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398-001 Oct 30, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398-001 Oct 30, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398-001 Oct 30, 2007 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for COMBIGAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1631293 2014/041 Ireland   Start Trial PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293 92462 Luxembourg   Start Trial PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293 2014C/042 Belgium   Start Trial PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293 14C0056 France   Start Trial PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKinsey
Moodys
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.